REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ...
Revolution Medicines (RVMD) announced encouraging antitumor activity and safety/tolerability data for RMC-6236, its RAS multi-selective inhibitor, in patients with previously treated pancreatic ductal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback